FDA proposes to focus on developing vaccines to deal with XBB variant

Illustration photo

The recommendation was supported by a 21-member advisory panel, and the panel's discussion suggests the FDA is likely to focus on the XBB.1.5 sub-variant. Vaccine makers Pfizer-BioNTech, Moderna and Novavax are developing vaccines to target XBB.1.5 as well as other circulating sub-variants.

Preclinical trial data from all three companies were presented to the advisory panel. The World Health Organization (WHO) and the European Medicines Agency (EMA) also recommended that the next round of Covid-19 vaccine boosters should focus on versions of XBB.

WHO issues new warning about Covid-19, US on guard against variant XBB.1.16

Source link: https://thanhnien.vn/fda-de-xuat-tap-trung-phat-trien-vac-xin-doi-pho-bien-the-xbb-185230616215432474.htm